Nan-Jing Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nan-Jing Peng has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Chin Hu
Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
9 shared publicationsYu-Li Chiu
Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
8 shared publicationsHung-Pin Chan
Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
4 shared publicationsRen-Shyan Liu
Natl Yang Ming Univ, Biomed Imaging Res Ctr, Taipei, Taiwan
4 shared publicationsChang-Ching Yu
From Department of Nuclear Medicine (H.-P.C., Y.-L.C., C.-C.Y., N.-J.P.) and Division of Hematology-Oncology, Department of Internal Medicine (S.-J.L.), Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan; Department of Information Engineering, I-Shou University, Kaohsiung City, Taiwan (C.-C.Y.); School of Medicine, National Yang-Ming University, Taipei, Taiwan (N.-J.P.).
2 shared publications- Sin-Di Lee
Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Taiwan
2 shared publications
Latest Publications
- Open Access
Compassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series
Brainstem tumors are heterogenous and cancerous glioma tumors arising from the midbrain, pons, and the medulla that are relatively common in children, accounting for 10% to 20% of all pediatric brain tumors. However, the prognosis of aggressive brainstem gliomas remains extremely poor despite aggressive treatment with chemotherapy and radiotherapy. That means there are many life-threatening patients who have exhausted all available treatment options and are beginning to face end-of-life stage. Therefore, the unique properties of highly selective heavy particle irradiation with boron neutron capture therapy (BNCT) may be well suited to prolong the lives of patients with end-stage brainstem gliomas. Herein, we report a case series of life-threatening patients with end-stage brainstem glioma who eligible for Emergency and Compassionate Use, in whom we performed a scheduled two fractions of salvage BNCT strategy with low treatment dosage each time. No patients experienced acute or late adverse events related to BNCT. There were 3 patients who relapsed after two fractionated BNCT treatment, characterized by younger age, lower T/N ratio, and receiving lower treatment dose. Therefore, two fractionated low-dose BNCT may be a promising treatment for end-stage brainstem tumors. For younger patients with low T/N ratios, more fractionated low-dose BNCT should be considered.
Open AccessCompassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series
Brainstem tumors are heterogenous and cancerous glioma tumors arising from the midbrain, pons, and the medulla that are relatively common in children, accounting for 10% to 20% of all pediatric brain tumors. However, the prognosis of aggressive brainstem gliomas remains extremely poor despite aggressive treatment with chemotherapy and radiotherapy. That means there are many life-threatening patients who have exhausted all available treatment options and are beginning to face end-of-life stage. Therefore, the unique properties of highly selective heavy particle irradiation with boron neutron capture therapy (BNCT) may be well suited to prolong the lives of patients with end-stage brainstem gliomas. Herein, we report a case series of life-threatening patients with end-stage brainstem glioma who eligible for Emergency and Compassionate Use, in whom we performed a scheduled two fractions of salvage BNCT strategy with low treatment dosage each time. No patients experienced acute or late adverse events related to BNCT. There were 3 patients who relapsed after two fractionated BNCT treatment, characterized by younger age, lower T/N ratio, and receiving lower treatment dose. Therefore, two fractionated low-dose BNCT may be a promising treatment for end-stage brainstem tumors. For younger patients with low T/N ratios, more fractionated low-dose BNCT should be considered.
- 1 December 2020
- Published by Edizioni Minerva Medica in The Quarterly Journal of Nuclear Medicine and Molecular Imaging
- Vol. 64 (4) , 393-399
Correlation of 18F-FDG uptake and thyroid cancer stem cells
BACKGROUND: 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography (F-18-FDG PET) has the potential to detect various types of cancers, including thyroid cancer (TC), at a potentially curable stage. Increased uptake of F-18-FDG was observed in anaplastic and poorly differentiated thyroid cancer cells, and PET-positive tumors are more likely to be resistant to I-131 treatment. As cancer stem cells (CSCs) possess a dedifferentiated phenotype and are resistant to many anticancer therapies, we hypothesized that the expression of CSC-related markers is correlated with the ability of tumor cells in TC to uptake FDG. METHODS: The present study cohort included 12 patients with TC. who underwent F-18-FDG PET/CT imaging before surgery. Quantitative polymerase chain reaction (QPCR) and immunohistochemical (IHC) staining were performed to analyze the expression patterns of gene markers related to embryonic stem (ES) cells and CSCs in TC. RESULTS: The mRNA expression levels of CSC- (CD133 and CD44) and ES-related genes (Oct4 and Nanog) were higher in TC tissue than in normal thyroid tissue, whereas the mRNA expression levels of thyroid-specific genes (Tg, TSHR, and TTF1) were higher in normal thyroid tissue than in TC tissue. There was a positive and statistically significant correlation between FDG uptake (SUVmax) of tumor and relative mRNA levels of CD133. CD44, Oct4, and Nang. The IHC results demonstrated that CD133 and Nanog were expressed in TC tissue but not in normal thyroid tissue, however, CD44 expression was observed in both TC and normal thyroid tissue. Comparisons of the clinicopathological parameters between TC tissues with low and high SUVmax demonstrated significant differences in protein level of CD133 but not in that of Nanog. CONCLUSIONS: The pre-therapeutic tumor SUVmax obtained from F-18-FDG PET/CT may be a potential predictor for evaluating the proportion of CSC population in individual patients with TC.
- 1 December 2020
- Published by Edizioni Minerva Medica in The Quarterly Journal of Nuclear Medicine and Molecular Imaging
- Vol. 64 (4) , 393-399
Correlation of 18F-FDG uptake and thyroid cancer stem cells
BACKGROUND: 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography (F-18-FDG PET) has the potential to detect various types of cancers, including thyroid cancer (TC), at a potentially curable stage. Increased uptake of F-18-FDG was observed in anaplastic and poorly differentiated thyroid cancer cells, and PET-positive tumors are more likely to be resistant to I-131 treatment. As cancer stem cells (CSCs) possess a dedifferentiated phenotype and are resistant to many anticancer therapies, we hypothesized that the expression of CSC-related markers is correlated with the ability of tumor cells in TC to uptake FDG. METHODS: The present study cohort included 12 patients with TC. who underwent F-18-FDG PET/CT imaging before surgery. Quantitative polymerase chain reaction (QPCR) and immunohistochemical (IHC) staining were performed to analyze the expression patterns of gene markers related to embryonic stem (ES) cells and CSCs in TC. RESULTS: The mRNA expression levels of CSC- (CD133 and CD44) and ES-related genes (Oct4 and Nanog) were higher in TC tissue than in normal thyroid tissue, whereas the mRNA expression levels of thyroid-specific genes (Tg, TSHR, and TTF1) were higher in normal thyroid tissue than in TC tissue. There was a positive and statistically significant correlation between FDG uptake (SUVmax) of tumor and relative mRNA levels of CD133. CD44, Oct4, and Nang. The IHC results demonstrated that CD133 and Nanog were expressed in TC tissue but not in normal thyroid tissue, however, CD44 expression was observed in both TC and normal thyroid tissue. Comparisons of the clinicopathological parameters between TC tissues with low and high SUVmax demonstrated significant differences in protein level of CD133 but not in that of Nanog. CONCLUSIONS: The pre-therapeutic tumor SUVmax obtained from F-18-FDG PET/CT may be a potential predictor for evaluating the proportion of CSC population in individual patients with TC.
- Open Access
- 31 August 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (9) , 657
Detection of Recurrent Cervical Cancer and Prediction of Its Patient Survival with Serum Squamous-Cell Carcinoma-Antigen and 2-[18F] Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography
Aim: To evaluate the usefulness of serum squamous-cell carcinoma antigen (SCC-Ag) and 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) for the detection of recurrent squamous-cell carcinoma (SqCC) of the uterine cervix, and its prediction of patient survival. Methods: FDG-PET/CT was performed for patients with serum SCC-Ag levels elevated to ≥1.5 ng/mL (Group 1) and those with suspicious recurrences without any increase in serum SCC-Ag levels (Group 2). The results were analyzed on the basis of histological data, disease progression and/or clinical follow-up. Recurrence was defined as evidence of recurrent lesions within 6 months of FDG-PET/CT. The outcome was determined using medical records. Results: In total, 88 consecutive patients with cervical SqCC cancer with suspected recurrence (62 in Group 1 and 26 in Group 2) were enrolled. Recurrences were observed in 55 patients (77.4% (48/62) in Group 1 vs. 26.9% (7/26) in Group 2, p < 0.001). The overall sensitivity, specificity and accuracy of serum SCC-Ag were 87.3%, 57.6% and 76.1%, respectively, and those of FDG-PET/CT were 98.2%, 90.9% and 95.5%, respectively; the corresponding values were 97.9%, 92.9% and 96.8% for Group 1 and 100%, 89.5% and 92.3% for Group 2. Surgical resection was performed for 16 patients. At the end of the study, 40.3% (25/62) of Group 1 patients and 88.5% (23/26) of Group 2 patients were alive (p < 0.001). The survival of patients who underwent surgical resection for recurrent tumors was higher than that of patients who did not undergo resection (62.5% (10/16) vs. 17.9% (7/39), p = 0.001). Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) derived from FDG-PET/CT showed significantly different in-patient survival. Conclusions: Serum SCC-Ag could predict tumor recurrence and the survival of patients with SqCC cervical cancer. As such, the surgical resection of limited recurrent disease, as determined using FDG-PET/CT, might improve the survival of patients with cervical cancer. MTV and TLG may serve as a prognostic biomarker of survival in patients with recurrent cervical cancer.
- 31 August 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (9) , 657
Open AccessDetection of Recurrent Cervical Cancer and Prediction of Its Patient Survival with Serum Squamous-Cell Carcinoma-Antigen and 2-[18F] Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography
Aim: To evaluate the usefulness of serum squamous-cell carcinoma antigen (SCC-Ag) and 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) for the detection of recurrent squamous-cell carcinoma (SqCC) of the uterine cervix, and its prediction of patient survival. Methods: FDG-PET/CT was performed for patients with serum SCC-Ag levels elevated to ≥1.5 ng/mL (Group 1) and those with suspicious recurrences without any increase in serum SCC-Ag levels (Group 2). The results were analyzed on the basis of histological data, disease progression and/or clinical follow-up. Recurrence was defined as evidence of recurrent lesions within 6 months of FDG-PET/CT. The outcome was determined using medical records. Results: In total, 88 consecutive patients with cervical SqCC cancer with suspected recurrence (62 in Group 1 and 26 in Group 2) were enrolled. Recurrences were observed in 55 patients (77.4% (48/62) in Group 1 vs. 26.9% (7/26) in Group 2, p < 0.001). The overall sensitivity, specificity and accuracy of serum SCC-Ag were 87.3%, 57.6% and 76.1%, respectively, and those of FDG-PET/CT were 98.2%, 90.9% and 95.5%, respectively; the corresponding values were 97.9%, 92.9% and 96.8% for Group 1 and 100%, 89.5% and 92.3% for Group 2. Surgical resection was performed for 16 patients. At the end of the study, 40.3% (25/62) of Group 1 patients and 88.5% (23/26) of Group 2 patients were alive (p < 0.001). The survival of patients who underwent surgical resection for recurrent tumors was higher than that of patients who did not undergo resection (62.5% (10/16) vs. 17.9% (7/39), p = 0.001). Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) derived from FDG-PET/CT showed significantly different in-patient survival. Conclusions: Serum SCC-Ag could predict tumor recurrence and the survival of patients with SqCC cervical cancer. As such, the surgical resection of limited recurrent disease, as determined using FDG-PET/CT, might improve the survival of patients with cervical cancer. MTV and TLG may serve as a prognostic biomarker of survival in patients with recurrent cervical cancer.
- 27 December 2019
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 34 (1) , 469-478
Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy
Background/Aim: Whole-body positron-emission tomography/computed tomography with the glucose analog 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET/CT) has been used to screen examinees for underlying malignancy in many countries. The aim of this study was to compare the potential value of FDG-PET/CT application in asymptomatic individuals with those with suspected malignancy. Patients and Methods: A total of 9,408 examinees underwent whole-body FDG-PET/CT at our hospital from July 2006 to August 2013. Three thousand and seven hundred asymptomatic individuals and 848 individuals with laboratory and clinical/radiologicaI suspicion of malignancy who had undergone FDG-PET/CT for cancer screening were recruited. The final confirmation of cancer and outcomes were based on a pathological report and continuous follow-up. Results: Forty-five out of 3,700 asymptomatic individuals (1.2%) had proven malignancy, and 42 of them (93.3%) were found by FDG-PET/CT. Two hundred and twelve out of 848 with suspected malignancy (25%) had proven malignancy, and 196 of them (92.5%) were detected by FDG-PET/CT. Most of these cancers in asymptomatic individuals were clinically at an early stage. The discovery rate in asymptomatic individuals and those with suspected malignancy was 1.1% and 23.1%, respectively. The overall survival of patients with cancer diagnosed with PET/CT was higher than those with suspected malignancy (78.6% vs. 48.5%, p
- 27 December 2019
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 34 (1) , 469-478
Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy
Background/Aim: Whole-body positron-emission tomography/computed tomography with the glucose analog 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET/CT) has been used to screen examinees for underlying malignancy in many countries. The aim of this study was to compare the potential value of FDG-PET/CT application in asymptomatic individuals with those with suspected malignancy. Patients and Methods: A total of 9,408 examinees underwent whole-body FDG-PET/CT at our hospital from July 2006 to August 2013. Three thousand and seven hundred asymptomatic individuals and 848 individuals with laboratory and clinical/radiologicaI suspicion of malignancy who had undergone FDG-PET/CT for cancer screening were recruited. The final confirmation of cancer and outcomes were based on a pathological report and continuous follow-up. Results: Forty-five out of 3,700 asymptomatic individuals (1.2%) had proven malignancy, and 42 of them (93.3%) were found by FDG-PET/CT. Two hundred and twelve out of 848 with suspected malignancy (25%) had proven malignancy, and 196 of them (92.5%) were detected by FDG-PET/CT. Most of these cancers in asymptomatic individuals were clinically at an early stage. The discovery rate in asymptomatic individuals and those with suspected malignancy was 1.1% and 23.1%, respectively. The overall survival of patients with cancer diagnosed with PET/CT was higher than those with suspected malignancy (78.6% vs. 48.5%, p
- Open Access
- 10 December 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-8
Which nasopharyngeal cancer patients need adaptive radiotherapy?
Adaptive radiotherapy (ART) has potential benefits in patients with nasopharyngeal cancer (NPC). This retrospective study aimed to identify the factors favoring ART. Forty NPC patients were retrospectively included in this study. All patients received two-phase, volumetric modulated arc radiotherapy (VMAT) and underwent a second computed tomography (CT) for the phase II ART. We generated phantom, non-ART plans by a hybrid method for comparison with ART plans. A paired t-test was used to evaluate the dose differences between these two plans. A subgroup analysis through a paired t-test was used to evaluate the factors favoring ART. The second CT images were captured at the median 22 fractions. The median total dose of the planning target volume-one (PTV-1) was 72 Gy, and the phase II dose was 16 Gy. The volumes of the ipsilateral parotid gland (23.2 vs. 19.2 ml, p < 0.000), contralateral parotid gland (23.0 vs. 18.4 ml, p < 0.000), clinical target volume-1 (CTV-1, 32.2 vs. 20.9 ml, p < 0.000), and PTV-1 (125.8 vs. 107.3 ml, p < 0.000) all shrunk significantly between these two CT simulation procedures. Among the nearby critical organs, only the ipsilateral parotid gland displayed significant dose reduction by the ART plan (5.3 vs. 6.0 Gy, p = 0.004). Compared to the phantom plan, the ART could significantly improve the PTV-1 target volume coverage of D98 (15.4 vs. 12.3 Gy, p < 0.000). Based on the D98 of PTV-1, the factors of a large initial weight (> 60 kg, p < 0.000), large body mass index (BMI) (> 21.5, p < 0.000), obvious weight loss (> 2.8 kg, p < 0.000), concurrent chemoradiotherapy (p < 0.000), and stages III–IV (p < 0.000) favored the use of ART. ART could significantly reduce the mean dose to the ipsilateral parotid gland. ART has dosimetrical benefit for patients with a heavy initial weight, large BMI, obvious weight loss, concurrent chemoradiotherapy, and cancer in stages III–IV.
- 10 December 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-8
Open AccessWhich nasopharyngeal cancer patients need adaptive radiotherapy?
Adaptive radiotherapy (ART) has potential benefits in patients with nasopharyngeal cancer (NPC). This retrospective study aimed to identify the factors favoring ART. Forty NPC patients were retrospectively included in this study. All patients received two-phase, volumetric modulated arc radiotherapy (VMAT) and underwent a second computed tomography (CT) for the phase II ART. We generated phantom, non-ART plans by a hybrid method for comparison with ART plans. A paired t-test was used to evaluate the dose differences between these two plans. A subgroup analysis through a paired t-test was used to evaluate the factors favoring ART. The second CT images were captured at the median 22 fractions. The median total dose of the planning target volume-one (PTV-1) was 72 Gy, and the phase II dose was 16 Gy. The volumes of the ipsilateral parotid gland (23.2 vs. 19.2 ml, p < 0.000), contralateral parotid gland (23.0 vs. 18.4 ml, p < 0.000), clinical target volume-1 (CTV-1, 32.2 vs. 20.9 ml, p < 0.000), and PTV-1 (125.8 vs. 107.3 ml, p < 0.000) all shrunk significantly between these two CT simulation procedures. Among the nearby critical organs, only the ipsilateral parotid gland displayed significant dose reduction by the ART plan (5.3 vs. 6.0 Gy, p = 0.004). Compared to the phantom plan, the ART could significantly improve the PTV-1 target volume coverage of D98 (15.4 vs. 12.3 Gy, p < 0.000). Based on the D98 of PTV-1, the factors of a large initial weight (> 60 kg, p < 0.000), large body mass index (BMI) (> 21.5, p < 0.000), obvious weight loss (> 2.8 kg, p < 0.000), concurrent chemoradiotherapy (p < 0.000), and stages III–IV (p < 0.000) favored the use of ART. ART could significantly reduce the mean dose to the ipsilateral parotid gland. ART has dosimetrical benefit for patients with a heavy initial weight, large BMI, obvious weight loss, concurrent chemoradiotherapy, and cancer in stages III–IV.
- 1 January 2018
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 14 (4) , 629-636
Biliary Motility Measured by Fatty Meal Cholescintigraphy in Patients After Endoscopic Treatment for Choledocholithiasis
Background: Endoscopic methods are well accepted as important treatments to clear the bile duct in patients with choledocholithiasis. However, little is known about bile dynamics after endoscopic treatment. Objective: The aim of this study was to assess the hepatic clearance and gallbladder function using fatty meal Cholescintigraphy (CS) in patients after endoscopic treatment for choledocholithiasis. Methods: Fatty meal CS was performed after intravenous injection of 8 mCi Tc-99m DISIDA. Hepatic clearance was calculated at 45 minutes (E45) after radiotracer injection. Gallbladder Ejection Fraction (GBEF) values were obtained at 30, 45, 60 and 75 minutes after fatty meal ingestion. Results: Thirty-nine patients were recruited. E45 was 39.5 +/- 12.7%, which was significantly lower than that in the cholecystectomized asymptomatic controls (66.2 9%, p < 0.001) in our prior study. The gallbladder was not properly filled in 13 patients. The GBEF values at 30, 45, 60 and 75 minutes were 82.7 +/- 14.6%, 90.4 +/- 12.8%, 90.4 +/- 11.1%, and 93.9 +/- 9.2%, respectively. GBEF was lower in the presence of gallstones, which reached statistical significance at 45 minutes and 60 minutes in the comparison of patients with and without gallstones (p < 0.05). Conclusion: Hepatic clearance in patients after endoscopic treatment for choledocholithiasis was generally lower. One-third of gallbladders lose their usual function. The GBEF was significantly reduced in the patients with gallstones. We suggested that GBEF with fatty meal stimulation could be used to follow patients after endoscopic treatment for choledocholithiasis.
- 1 January 2018
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 14 (4) , 629-636
Biliary Motility Measured by Fatty Meal Cholescintigraphy in Patients After Endoscopic Treatment for Choledocholithiasis
Background: Endoscopic methods are well accepted as important treatments to clear the bile duct in patients with choledocholithiasis. However, little is known about bile dynamics after endoscopic treatment. Objective: The aim of this study was to assess the hepatic clearance and gallbladder function using fatty meal Cholescintigraphy (CS) in patients after endoscopic treatment for choledocholithiasis. Methods: Fatty meal CS was performed after intravenous injection of 8 mCi Tc-99m DISIDA. Hepatic clearance was calculated at 45 minutes (E45) after radiotracer injection. Gallbladder Ejection Fraction (GBEF) values were obtained at 30, 45, 60 and 75 minutes after fatty meal ingestion. Results: Thirty-nine patients were recruited. E45 was 39.5 +/- 12.7%, which was significantly lower than that in the cholecystectomized asymptomatic controls (66.2 9%, p < 0.001) in our prior study. The gallbladder was not properly filled in 13 patients. The GBEF values at 30, 45, 60 and 75 minutes were 82.7 +/- 14.6%, 90.4 +/- 12.8%, 90.4 +/- 11.1%, and 93.9 +/- 9.2%, respectively. GBEF was lower in the presence of gallstones, which reached statistical significance at 45 minutes and 60 minutes in the comparison of patients with and without gallstones (p < 0.05). Conclusion: Hepatic clearance in patients after endoscopic treatment for choledocholithiasis was generally lower. One-third of gallbladders lose their usual function. The GBEF was significantly reduced in the patients with gallstones. We suggested that GBEF with fatty meal stimulation could be used to follow patients after endoscopic treatment for choledocholithiasis.
- 1 December 2017
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (12) , 971-972
Interruption of the Inferior Vena Cava With Azygos Continuation
This report describes a 19-year-old man with interruption of the inferior vena cava with azygos continuation. Both radionuclide venography and MRI clearly showed venous return of the lower limbs through prominent collateral systems.
- 1 December 2017
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (12) , 971-972
Interruption of the Inferior Vena Cava With Azygos Continuation
This report describes a 19-year-old man with interruption of the inferior vena cava with azygos continuation. Both radionuclide venography and MRI clearly showed venous return of the lower limbs through prominent collateral systems.
- 1 August 2017
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (8) , 641-642
Incidental Thyroid Nodule Noted on Intra-arterial Hepatic MAA Scan Before 90Y-SIRT
We report a case of a 61-year-old man who had recurrent hepatocellular carcinoma admitted for series evaluation before 90Y selective internal radiotherapy (SIRT). Intra-arterial hepatic 99mTc macroaggregated albumin scan before 90Y-SIRT revealed a 2.7-cm incidental low-density thyroid nodule with hot uptake. 99mTcO4 scan revealed corresponding hot uptake in the thyroid nodule with near background uptake of normal thyroid tissue, favored autonomous nodule. After 90Y-microsphere SIRT, bremstrallung imaging revealed no 90Y-microsphere deposition to thyroid.
- 1 August 2017
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (8) , 641-642
Incidental Thyroid Nodule Noted on Intra-arterial Hepatic MAA Scan Before 90Y-SIRT
We report a case of a 61-year-old man who had recurrent hepatocellular carcinoma admitted for series evaluation before 90Y selective internal radiotherapy (SIRT). Intra-arterial hepatic 99mTc macroaggregated albumin scan before 90Y-SIRT revealed a 2.7-cm incidental low-density thyroid nodule with hot uptake. 99mTcO4 scan revealed corresponding hot uptake in the thyroid nodule with near background uptake of normal thyroid tissue, favored autonomous nodule. After 90Y-microsphere SIRT, bremstrallung imaging revealed no 90Y-microsphere deposition to thyroid.
- Open Access
- 1 November 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (44) , e5131
Application of whole-body FDG-PET for cancer screening in a cohort of hospital employees
Whole-body positron emission tomography/computed tomography with the glucose analog 2-[F]fluoro-2-deoxy-D-glucose (FDG-PET/CT) has been extensively used to screen for underlying malignancies in asymptomatic individuals. We were able to survey a cohort of hospital employees using FDG-PET/CT and to report the results herein.A total of 116 hospital employees older than 55 years old were offered whole-body FDG-PET in our hospital. Ninety-seven employees (83.6%) completed the assessment from February 2014 to August 2014 in our PET center. The final confirmation of cancer was based on pathologic examination and follow-up after more than 1 year.Among the 97 participants, 92 were asymptomatic and 5 presented with previously diagnosed cancers. Six of the 92 asymptomatic participants (6.6%) with significant nodular lesions were referred for histological or cytological evaluation of the possibility of malignancy, and 1 case was considered clinically important and required surgical resection. The cancer discovery rate was 3.3% (3/92) with positive predictive value of 50% (3/6). In the 5 participants with previously identified cancers, no recurrence or metastasis was detected.The offer of whole-body FDG-PET for cancer screening was welcomed with enthusiasm by most of the hospital employees. PET/CT combines the merits of PET and CT and can be administered to and provide benefits to a select group of hospital employees.
- 1 November 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (44) , e5131
Open AccessApplication of whole-body FDG-PET for cancer screening in a cohort of hospital employees
Whole-body positron emission tomography/computed tomography with the glucose analog 2-[F]fluoro-2-deoxy-D-glucose (FDG-PET/CT) has been extensively used to screen for underlying malignancies in asymptomatic individuals. We were able to survey a cohort of hospital employees using FDG-PET/CT and to report the results herein.A total of 116 hospital employees older than 55 years old were offered whole-body FDG-PET in our hospital. Ninety-seven employees (83.6%) completed the assessment from February 2014 to August 2014 in our PET center. The final confirmation of cancer was based on pathologic examination and follow-up after more than 1 year.Among the 97 participants, 92 were asymptomatic and 5 presented with previously diagnosed cancers. Six of the 92 asymptomatic participants (6.6%) with significant nodular lesions were referred for histological or cytological evaluation of the possibility of malignancy, and 1 case was considered clinically important and required surgical resection. The cancer discovery rate was 3.3% (3/92) with positive predictive value of 50% (3/6). In the 5 participants with previously identified cancers, no recurrence or metastasis was detected.The offer of whole-body FDG-PET for cancer screening was welcomed with enthusiasm by most of the hospital employees. PET/CT combines the merits of PET and CT and can be administered to and provide benefits to a select group of hospital employees.
- 1 December 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 132 (22) , 2164-2166
Incidental Finding of Solitary Plasmacytoma in Thallium-201 Myocardial Perfusion Scintigraphy
- 1 December 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 132 (22) , 2164-2166
Incidental Finding of Solitary Plasmacytoma in Thallium-201 Myocardial Perfusion Scintigraphy